Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV
- 1 September 2011
- Vol. 29 (38) , 6606-6613
- https://doi.org/10.1016/j.vaccine.2011.06.111
Abstract
No abstract availableKeywords
Funding Information
- NIH (1U03AI06198801)
This publication has 49 references indexed in Scilit:
- Actin-based motility drives baculovirus transit to the nucleus and cell surfaceThe Journal of cell biology, 2010
- Effect of mucosal and systemic immunization with virus‐like particles of severe acute respiratory syndrome coronavirus in miceImmunology, 2010
- Probing local innate immune responses after mucosal immunisationJournal of Immune Based Therapies and Vaccines, 2010
- A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivoVirology, 2009
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008
- Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVVaccine, 2007
- Immune responses against severe acute respiratory syndrome coronavirus induced by virus‐like particles in miceImmunology, 2007
- Vaccines to prevent severe acute respiratory syndrome coronavirus-induced diseaseVirus Research, 2007
- Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)Vaccine, 2006
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004